Copy to clipboard 
Entirety Biomedical closed a $1.2 million seed financing round to advance toward first-in-human clinical trials.
The round was led by NuFund Venture Group, with participation from Michigan Rise, Union Heritage, Revere Partners, Community Equity Partners, American Society of Plastic Surgeons, and Mass Medical Angels, among others.
Entirety is developing a portfolio of absorbable magnesium implant systems with its patented Curasorb alloy, designed to deliver the strength and handling characteristics of traditional titanium implants, then safely absorb once healing is complete. The company is initially focused on lower extremity and maxillofacial fixation systems.
The non-coated plate-and-screw implant systems are designed to integrate seamlessly into existing surgical workflows. The technology platform is intended to support multiple orthopedic and maxillofacial applications.
The company completed its first preclinical study in 2024 and is currently conducting three additional preclinical studies. Early data have demonstrated strong osseointegration and will inform the company’s planned first-in-human clinical trial of its headless compression screw system for lower extremity fixation.
Jake Edick, CEO and Co-Founder of Entirety Biomedical, said, “We’re removing adoption barriers for absorbable implants by giving surgeons a true alternative to permanent hardware—using the same procedures, cost structures, and reimbursement models they already know. Our goal is to redefine orthopedic fixation so patients can heal naturally, recover faster, and avoid the long-term risks and trauma associated with permanent hardware left in the body.”
Source: Entirety Biomedical
Entirety Biomedical closed a $1.2 million seed financing round to advance toward first-in-human clinical trials.
The round was led by NuFund Venture Group, with participation from Michigan Rise, Union Heritage, Revere Partners, Community Equity Partners, American Society of Plastic Surgeons, and Mass Medical Angels, among others.
Entirety...
Entirety Biomedical closed a $1.2 million seed financing round to advance toward first-in-human clinical trials.
The round was led by NuFund Venture Group, with participation from Michigan Rise, Union Heritage, Revere Partners, Community Equity Partners, American Society of Plastic Surgeons, and Mass Medical Angels, among others.
Entirety is developing a portfolio of absorbable magnesium implant systems with its patented Curasorb alloy, designed to deliver the strength and handling characteristics of traditional titanium implants, then safely absorb once healing is complete. The company is initially focused on lower extremity and maxillofacial fixation systems.
The non-coated plate-and-screw implant systems are designed to integrate seamlessly into existing surgical workflows. The technology platform is intended to support multiple orthopedic and maxillofacial applications.
The company completed its first preclinical study in 2024 and is currently conducting three additional preclinical studies. Early data have demonstrated strong osseointegration and will inform the company’s planned first-in-human clinical trial of its headless compression screw system for lower extremity fixation.
Jake Edick, CEO and Co-Founder of Entirety Biomedical, said, “We’re removing adoption barriers for absorbable implants by giving surgeons a true alternative to permanent hardware—using the same procedures, cost structures, and reimbursement models they already know. Our goal is to redefine orthopedic fixation so patients can heal naturally, recover faster, and avoid the long-term risks and trauma associated with permanent hardware left in the body.”
Source: Entirety Biomedical
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
